Cemiplimab (Libatyo) approved by FDA for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)

The approval was based on data from the Phase III clinical trial (n=710), called EMPOWER-Lung 1 that demonstrated the drug extended overall survival compared to chemotherapy in study patients.

Source:

Biospace Inc.